TY - JOUR
T1 - HLA Class I Analysis Provides Insight Into the Genetic and Epigenetic Background of Immune Evasion in Colorectal Cancer With High Microsatellite Instability
AU - Kawazu, Masahito
AU - Ueno, Toshihide
AU - Saeki, Koichi
AU - Sax, Nicolas
AU - Togashi, Yosuke
AU - Kanaseki, Takayuki
AU - Chida, Keigo
AU - Kishigami, Fumishi
AU - Sato, Kazuhito
AU - Kojima, Shinya
AU - Otsuka, Masafumi
AU - Kawazoe, Akihito
AU - Nishinakamura, Hitomi
AU - Yuka, Maeda
AU - Yamamoto, Yoko
AU - Yamashita, Kazuo
AU - Inoue, Satoshi
AU - Tanegashima, Tokiyoshi
AU - Matsubara, Daisuke
AU - Tane, Kenta
AU - Tanaka, Yosuke
AU - Iinuma, Hisae
AU - Hashiguchi, Yojiro
AU - Hazama, Shoichi
AU - Khor, Seik Soon
AU - Tokunaga, Katsushi
AU - Tsuboi, Masahiro
AU - Niki, Toshiro
AU - Eto, Masatoshi
AU - Shitara, Kohei
AU - Torigoe, Toshihiko
AU - Ishihara, Soichiro
AU - Aburatani, Hiroyuki
AU - Haeno, Hiroshi
AU - Nishikawa, Hiroyoshi
AU - Mano, Hiroyuki
N1 - Funding Information:
The authors thank Ms Saori Sugaya and Ms Reina Takeyama for their technical assistance. Seik-Soon Khor's current affiliation is Genome Medical Science Project, National Center for Global Health and Medicine, Japan. Katsushi Tokunaga's current affiliation is Genome Medical Science Project, National Center for Global Health and Medicine, Tokyo, Japan. Masahito Kawazu, PhD (Conceptualization: Lead; Formal analysis: Lead; Funding acquisition: Equal; Investigation: Lead; Project administration: Equal; Visualization: Lead; Writing – original draft: Lead; Writing – review & editing: Equal). Toshihide Ueno, PhD (Formal analysis: Equal; Investigation: Equal), Koichi Saeki, MS (Formal analysis: Equal; Investigation: Equal; Visualization: Equal). Nicolas Sax, PhD (Formal analysis: Equal; Investigation: Equal; Visualization: Equal). Yosuke Togashi, PhD (Data curation: Equal; Resources: Equal). Takayuki Kanaseki, PhD (Investigation: Equal). Keigo Chida, MD (Data curation: Equal; Resources: Equal). Fumishi Kishigami, MD (Data curation: Equal; Resources: Equal). Kazuhito Sato, PhD (Data curation: Equal; Formal analysis: Equal; Investigation: Equal; Resources: Equal). Shinya Kojima, MS (Formal analysis: Equal; Investigation: Equal). Masafumi Otsuka, MD (Investigation: Equal). Akihito Kawazoe, PhD (Data curation: Equal; Resources: Equal). Hitomi Nishinakamura, PhD (Investigation: Supporting). Yuka Maeda, PhD (Investigation: Supporting). Yoko Yamamoto, PhD (Data curation: Equal; Investigation: Equal; Resources: Equal). Kazuo Yamashita, PhD (Formal analysis: Equal; Investigation: Equal; Visualization: Equal; Writing – original draft: Equal). Satoshi Inoue, PhD (Investigation: Supporting). Tokiyoshi Tanegashima, PhD (Data curation: Equal; Resources: Equal). Daisuke Matsubara, PhD (Data curation: Equal; Resources: Equal). Kenta Tane, MD (Data curation: Equal; Resources: Equal). Yosuke Tanaka, PhD (Investigation: Supporting). Hisae Iinuma, PhD (Data curation: Equal; Resources: Equal). Yojiro Hashiguchi, PhD (Data curation: Equal; Resources: Equal). Shoichi Hazama, PhD (Data curation: Equal; Resources: Equal). Seik-Soon Khor, PhD (Investigation: Supporting). Katsushi Tokunaga, PhD (Funding acquisition: Supporting; Investigation: Supporting). Masahiro Tsuboi, PhD (Data curation: Equal; Resources: Equal). Toshiro Niki, PhD (Data curation: Equal; Resources: Equal). Masatoshi Eto, PhD (Data curation: Equal; Resources: Equal). Kohei Shitara, PhD (Data curation: Equal; Resources: Equal). Toshihiko Torigoe, PhD (Investigation: Supporting; Resources: Equal). Soichiro Ishihara, PhD (Data curation: Equal; Resources: Equal). Hiroyuki Aburatani, PhD (Funding acquisition: Equal; Project administration: Equal). Hiroshi Haeno, PhD (Formal analysis: Equal; Funding acquisition: Supporting; Investigation: Equal; Visualization: Equal; Writing – original draft: Equal). Hiroyoshi Nishikawa, PhD (Funding acquisition: Equal; Investigation: Supporting). Hiroyuki Mano, PhD (Funding acquisition: Equal; Project administration: Equal; Supervision: Lead; Writing – review & editing: Equal). Funding This study was supported by grants from the National Cancer Center Research and Development Fund (29-A-6, H. Haeno), the Japan Agency for Medical Research and Development (AMED) (JP18kk0205012 to K. Tokunaga; JP19km0405205 to K. Tokunaga; JP19cm0106504 to H. Haeno; JP17am0001001 to H. Mano; JP15cm0106085 to S. Hazama; JP19cm0106502 to M. Kawazu, S. Ishihara, and H. Aburatani; JP16cm0106301 to H. Nishikawa; JP18gm1010005 to H. Nishikawa, JP19ae0101074 to H. Nishikawa), the Japan Society for the Promotion of Science (KAKENHI, 17J00386 to K. Sato; 16K07143 and 21H02772 to M. Kawazu), the UBE Industries Foundation (to M. Kawazu), the Kobayashi Foundation for Cancer Research (to M. Kawazu), and the Ministry of Education, Culture, Sports, Science and Technology of Japan (17H06162 to H. Nishikawa).
Funding Information:
Funding This study was supported by grants from the National Cancer Center Research and Development Fund (29-A-6, H. Haeno), the Japan Agency for Medical Research and Development (AMED) (JP18kk0205012 to K. Tokunaga; JP19km0405205 to K. Tokunaga; JP19cm0106504 to H. Haeno; JP17am0001001 to H. Mano; JP15cm0106085 to S. Hazama; JP19cm0106502 to M. Kawazu, S. Ishihara, and H. Aburatani; JP16cm0106301 to H. Nishikawa; JP18gm1010005 to H. Nishikawa, JP19ae0101074 to H. Nishikawa), the Japan Society for the Promotion of Science (KAKENHI, 17J00386 to K. Sato; 16K07143 and 21H02772 to M. Kawazu), the UBE Industries Foundation (to M. Kawazu), the Kobayashi Foundation for Cancer Research (to M. Kawazu), and the Ministry of Education, Culture, Sports, Science and Technology of Japan (17H06162 to H. Nishikawa).
Publisher Copyright:
© 2022 AGA Institute
PY - 2022/3
Y1 - 2022/3
N2 - Background & Aims: A detailed understanding of antitumor immunity is essential for optimal cancer immune therapy. Although defective mutations in the B2M and HLA-ABC genes, which encode molecules essential for antigen presentation, have been reported in several studies, the effects of these defects on tumor immunity have not been quantitatively evaluated. Methods: Mutations in HLA-ABC genes were analyzed in 114 microsatellite instability–high colorectal cancers using a long-read sequencer. The data were further analyzed in combination with whole-exome sequencing, transcriptome sequencing, DNA methylation array, and immunohistochemistry data. Results: We detected 101 truncating mutations in 57 tumors (50%) and loss of 61 alleles in 21 tumors (18%). Based on the integrated analysis that enabled the immunologic subclassification of microsatellite instability–high colorectal cancers, we identified a subtype of tumors in which lymphocyte infiltration was reduced, partly due to reduced expression of HLA-ABC genes in the absence of apparent genetic alterations. Survival time of patients with such tumors was shorter than in patients with other tumor types. Paradoxically, tumor mutation burden was highest in the subtype, suggesting that the immunogenic effect of accumulating mutations was counterbalanced by mutations that weakened immunoreactivity. Various genetic and epigenetic alterations, including frameshift mutations in RFX5 and promoter methylation of PSMB8 and HLA-A, converged on reduced expression of HLA-ABC genes. Conclusions: Our detailed immunogenomic analysis provides information that will facilitate the improvement and development of cancer immunotherapy.
AB - Background & Aims: A detailed understanding of antitumor immunity is essential for optimal cancer immune therapy. Although defective mutations in the B2M and HLA-ABC genes, which encode molecules essential for antigen presentation, have been reported in several studies, the effects of these defects on tumor immunity have not been quantitatively evaluated. Methods: Mutations in HLA-ABC genes were analyzed in 114 microsatellite instability–high colorectal cancers using a long-read sequencer. The data were further analyzed in combination with whole-exome sequencing, transcriptome sequencing, DNA methylation array, and immunohistochemistry data. Results: We detected 101 truncating mutations in 57 tumors (50%) and loss of 61 alleles in 21 tumors (18%). Based on the integrated analysis that enabled the immunologic subclassification of microsatellite instability–high colorectal cancers, we identified a subtype of tumors in which lymphocyte infiltration was reduced, partly due to reduced expression of HLA-ABC genes in the absence of apparent genetic alterations. Survival time of patients with such tumors was shorter than in patients with other tumor types. Paradoxically, tumor mutation burden was highest in the subtype, suggesting that the immunogenic effect of accumulating mutations was counterbalanced by mutations that weakened immunoreactivity. Various genetic and epigenetic alterations, including frameshift mutations in RFX5 and promoter methylation of PSMB8 and HLA-A, converged on reduced expression of HLA-ABC genes. Conclusions: Our detailed immunogenomic analysis provides information that will facilitate the improvement and development of cancer immunotherapy.
KW - Antitumor Immunity
KW - Class I Major Histocompatibility Complex
KW - Long-Read Sequencer
KW - Microsatellite Instability–High Colorectal Cancer
UR - http://www.scopus.com/inward/record.url?scp=85124584630&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85124584630&partnerID=8YFLogxK
U2 - 10.1053/j.gastro.2021.10.010
DO - 10.1053/j.gastro.2021.10.010
M3 - Article
C2 - 34687740
AN - SCOPUS:85124584630
SN - 0016-5085
VL - 162
SP - 799
EP - 812
JO - Gastroenterology
JF - Gastroenterology
IS - 3
ER -